Nidek v. Visx
This article was originally published in The Gray Sheet
Executive Summary
Nidek is now permitted to recommence action in its antitrust allegations against Visx following U.S. District Court Judge Charles Breyer's decision to lift a stay currently in place on the case. Judge Breyer's decision follows a Dec. 6 ruling by International Trade Commission Administrative Law Judge Debra Morriss that Nidek does not infringe two Visx LASIK patents covering the apparatus and method for performing the ophthalmic surgical procedure (1"The Gray Sheet" Dec. 13, p. 15)
You may also be interested in...
Visx v. Nidek ITC LASIK Ruling May Open Door For Bausch & Lomb, Others
A recent ruling by the International Trade Commission weakens, at least temporarily, the patent position of Visx and co-licensor Summit Technology in the rapidly growing laser-assisted in situ keratomileusis (LASIK) market, and creates an opening for a formidable competitor, Bausch & Lomb, whose Technolas LASIK device awaits FDA approval.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.